Genmab stock
GMAB.COCPHGenmab A/S, HealthcareISIN DK0010272202
66Score 66 out of 100, Neutral
Price and trend
79 / 100
Price history
+80% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 73% above it.
Since August 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 70).
The price is 9.8% below its 52-week high. Largest decline in 20 years: 94% (May 2007 to November 2011).
Chart figures for advanced users
- SMA 50$398.35
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$302.99
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)70
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$225.91
- The lowest closing price of the last twelve months.
- Resistance$579.89
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Genmab A/S belongs to the Biotechnology industry (Denmark) and, with a market value of $32.18B, is number 11 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $3.86B (down 82.1% year on year) and earnings of $999.19M (down 87.3%).
- MEQIRI Score 66 out of 100 (Neutral): rank 196 of 702 in Healthcare, median 53.
Show more
- The P/E is 44.5 (Biotechnology median 21.7, own median of recent years 42.9).
- Our model puts fair value at $457.84, with the price 14% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Analysts expect strong earnings growthUp 43.7% a year through 2028 (estimates from 13 analysts).
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 92
- Earnings turn into cashFree cash flow 116% of earnings over the last 12 months.Fundamentals 92
Weaknesses
- Revenue shrinkingRevenue down 17.5% a year since 2020.Growth 5
- Earnings per share fallingDown 26.1% a year since 2020.Growth 5
- Volatile share priceVolatility 47% a year over the last 12 months.
Its standout strengths are momentum and fundamentals, while valuation and growth hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among stocks ranked 101 to 1,000.
From 2016 to 2025, 13 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What drives the risk
- high price swings
- price up very strongly over the past year
What lowers it
- solid fundamentals
- low growth grade (crashed less often in the backtest)
- stable momentum
Valuation
Valuation signal
Fairly valuedIn our model the price counts as cheap below $327.03 and expensive above $763.06 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $660.50 (cash-flow model) and $255.17 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 9.6%. At 10.6% the fair value would be $402.19, at 8.6% it would be $537.43.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (21.7).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2025, revenue fell 82.1% on the prior year. Revenue has grown strongly since 2006, at around 19% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 92%, operating 34%, net 26%. Last 12 months: net 17%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with moderate debt and comfortable interest coverage.
Earnings
- Next earnings
- 24 Feb 2027in 103 days
- Last reported
- 5 Nov 2026EPS reported 36.81 (expected 23.11)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- 11.86+0.2%
- Revenue
- $4.51B+0.5%
- Earnings per share
- 17.62+1.8%
- Revenue
- $5.45B+2.4%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +5.7%2026 guidance raised: revenue of $4.3 billion to $4.5 billion (5% higher than before) and operating profit of $1.1 billion to $1.4 billion (7% higher).
“Compared with our previous guidance, we now expect to deliver 5% higher revenue and 7% higher operating profit.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q2 2026), read by AI.
What happened at Genmab
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 66
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Samsung Biologics207940.KS $50.56B68
- BeOne MedicinesONC $44.45B70
- Revolution MedicinesRVMD $38.14B41
- Celltrion068270.KS $35.82B64
- Roivant SciencesROIV $28.98B48
- InsmedINSM $25.9B43
- WuXi Biologics (Cayman)2269.HK $25.32B73
- United TherapeuticsUTHR $25.27B81
ETFs that hold Genmab
Held by 105 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Pharma Breakthrough UCITS ETFETLI | 3.94% | 0.49% | €26.29M |
| iShares Healthcare Innovation UCITS ETF2B78 | 2.57% | 0.40% | €1.5B |
| Xtrackers MSCI Nordic UCITS ETF 1DXDN0 | 2.13% | 0.30% | €1.19B |
Show 5 more
| Amundi MSCI Europe Ex EMU ESG Selection UCITS ETF Acc540H | 1.72% | 0.30% | €183.15M |
| iShares STOXX Europe 600 Health Care UCITS ETF (DE)EXV4 | 1.62% | 0.46% | €722.41M |
| Xtrackers MSCI Europe Health Care Screened UCITS ETF 1CDXSE | 1.62% | 0.17% | €362.64M |
| iShares MSCI Europe Health Care Sector UCITS ETFESIH | 1.61% | 0.18% | €953.22M |
| State Street SPDR MSCI Europe Health Care UCITS ETFSPYH | 1.57% | 0.18% | €652.41M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = DKK 6.7461)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 24 Apr 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.